Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development

References

• Osswald M, Solecki G, Wick W, et al. A malignant cellular network in gliomas: potential clinical implications. Neuro Oncol. 2016;18(4):479–485.
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–198.
   PubMed Web of Science ®Google Scholar
• Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3–8.
   PubMed Web of Science ®Google Scholar
• Dandy WL. Removal of the right cerebral hemisphere for certain tumors with hemiplegia. JAMA. 1928;90:823–825.
   Google Scholar
• Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392–401.
   PubMed Web of Science ®Google Scholar
• Upadhyay N, Waldman AD. Conventional MRI evaluation of gliomas. Br J Radiol. 2011;84 Spec(No 2):S107–11.
   Google Scholar
• Johnson DR, Guerin JB, Ruff MW, et al. Glioma response assessment: classic pitfalls, novel confounders, and emerging imaging tools. Br J Radiol. 2019;92(1094):20180730.
   PubMed Web of Science ®Google Scholar
• Kelly PJ, Daumas-Duport C, Kispert DB, et al. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987;66(6):865–874.
   PubMed Web of Science ®Google Scholar
• Hadjipanayis CG, Widhalm G, Stummer W. What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas? Neurosurgery. 2015;77(5):663–673.
   PubMed Web of Science ®Google Scholar
• Glenn CA, Baker CM, Conner AK, et al. An examination of the role of supramaximal resection of temporal lobe glioblastoma multiforme. World Neurosurg. 2018;114:e747–e55.
   PubMed Web of Science ®Google Scholar
• la Fougere C, Suchorska B, Bartenstein P, et al. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol. 2011;13(8):806–819.
   PubMed Web of Science ®Google Scholar
• Xiao J, Jin Y, Nie J, et al. Diagnostic and grading accuracy of (18)F-FDOPA PET and PET/CT in patients with gliomas: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):767.
   PubMed Web of Science ®Google Scholar
• Pafundi DH, Laack NN, Youland RS, et al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol. 2013;15(8):1058–1067.
   PubMed Web of Science ®Google Scholar
• Walker MD, Alexander E Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333–343.
   PubMed Web of Science ®Google Scholar
• Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5(10):1725–1731.
   PubMed Web of Science ®Google Scholar
• Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol. 2002;20(6):1635–1642.
   PubMed Web of Science ®Google Scholar
• Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359(9311):1011–1018.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–2508.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820.
   PubMed Web of Science ®Google Scholar
• Romain Appay CD, Maurage C-A, Alenton A, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 2019 Dec 17;21(12):1485–1486.
   PubMed Web of Science ®Google Scholar
• Venteicher AS, Tirosh I, Hebert C, et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017;355:6332.
   Web of Science ®Google Scholar
• Wick W, Weller M, van den Bent M, et al. MGMT testing–the challenges for biomarker-based glioma treatment. Nat Rev Neurol. 2014;10(7):372–385.
   PubMed Web of Science ®Google Scholar
• Radke J, Koch A, Pritsch F, et al. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients. Acta Neuropathol Commun. 2019;7(1):89.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085–4091.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Tzaridis T, Mack F, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019;393(10172):678–688.
   PubMed Web of Science ®Google Scholar
• Morales J, Li L, Fattah FJ, et al. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr. 2014;24(1):15–28.
   PubMed Web of Science ®Google Scholar
• Khasraw M, McDonald KL, Rosenthal M, et al. A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM). J Clin Oncol. 2019;suppl no: 15, 2011–2011.
   PubMed Web of Science ®Google Scholar
• Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469–474.
   PubMed Web of Science ®Google Scholar
• Pansuriya TC, van Eijk R, d’Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in ollier disease and maffucci syndrome. Nat Genet. 2011;43(12):1256–1261.
   PubMed Web of Science ®Google Scholar
• Flavahan WA, Drier Y, Liau BB, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016;529(7584):110–114.
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Penas-Prado M, Peters KB, et al. Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma. J Clin Oncol. 2018 May 20;36(15):2002–2002.
   PubMedGoogle Scholar
• Platten M, Schilling D, Bunse L, et al. A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16). J Clin Oncol. 2018;suppl no:15, 2001–2001.
   Web of Science ®Google Scholar
• Golub D, Iyengar N, Dogra S, et al. Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics. Front Oncol. 2019;9:417.
   PubMed Web of Science ®Google Scholar
• Natsame A, Wakabayashi T, Miyakita Y, et al. Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas. J Clin Oncol. 2019;37(15): 2004–2004.
   Web of Science ®Google Scholar
• Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189–193.
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Maciejewski JP, Wilmink JW, et al. Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene. 2018;37(15):1949–1960.
   PubMed Web of Science ®Google Scholar
• Lu Y, Kwintkiewicz J, Liu Y, et al. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. Cancer Res. 2017;77(7):1709–1718.
   PubMed Web of Science ®Google Scholar
• Wahl DR, Dresser J, Wilder-Romans K, et al. Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. Cancer Res. 2017;77(4):960–970.
   PubMed Web of Science ®Google Scholar
• McBrayer SK, Mayers JR, DiNatale GJ, et al. Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell. 2018;175(1):101–16 e25.
   PubMed Web of Science ®Google Scholar
• Tonjes M, Barbus S, Park YJ, et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med. 2013;19(7):901–908.
   PubMed Web of Science ®Google Scholar
• Glutaminase Inhibitor Telaglenastat (CB-839). 2017 cited 2019 Oct 29. Company version 4. Available from: https://www.calithera.com/glutaminase-inhibitor-cb-839/
   Google Scholar
• CB-839 With Radiation Therapy and Temozolomide in Treating Participants With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma [Internet. [ cited 2019 October 8]; Available from: https://clinicaltrials.gov/ct2/show/NCT03528642
   Google Scholar
• Kizilbash SH, McBrayer SK, Port J, et al. A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642). J Clin Oncol. 2019;37:TPS2075.
   Web of Science ®Google Scholar
• Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66(20):9852–9861.
   PubMed Web of Science ®Google Scholar
• Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–343.
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–350.
   PubMed Web of Science ®Google Scholar
• Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016;374(14):1344–1355.
   PubMed Web of Science ®Google Scholar
• Osswald M, Jung E, Sahm F, et al. Brain tumour cells interconnect to a functional and resistant network. Nature. 2015;528(7580):93–98.
   PubMed Web of Science ®Google Scholar
• Jaraiz-Rodriguez M, Tabernero MD, Gonzalez-Tablas M, et al. A Short Region of Connexin43 Reduces Human Glioma Stem Cell Migration, Invasion, and Survival through Src, PTEN, and FAK. Stem Cell Reports. 2017;9(2):451–463.
   PubMed Web of Science ®Google Scholar
• Wang J, Yang ZY, Guo YF, et al. Targeting different domains of gap junction protein to control malignant glioma. Neuro Oncol. 2018;20(7):885–896.
   PubMed Web of Science ®Google Scholar
• Ayuso JM, Monge R, Martinez-Gonzalez A, et al. Glioblastoma on a microfluidic chip: generating pseudopalisades and enhancing aggressiveness through blood vessel obstruction events. Neuro Oncol. 2017;19(4):503–513.
   PubMed Web of Science ®Google Scholar
• Xu H, Rahimpour S, Nesvick CL, et al. Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy. Oncotarget. 2015;6(14):11882–11893.
   PubMedGoogle Scholar
• Bangasser BL, Rosenfeld SS, Odde DJ. Determinants of maximal force transmission in a motor-clutch model of cell traction in a compliant microenvironment. Biophys J. 2013;105(3):581–592.
   PubMed Web of Science ®Google Scholar
• Venkatesh HS, Tam LT, Woo PJ, et al. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature. 2017;549(7673):533–537.
   PubMed Web of Science ®Google Scholar
• Qu M, Qiu BO, Xiong W, et al. Expression of a-disintegrin and metalloproteinase 10 correlates with grade of malignancy in human glioma. Oncol Lett. 2015;9(5):2157–2162.
   PubMed Web of Science ®Google Scholar
• Witters L, Scherle P, Friedman S, et al. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 2008;68(17):7083–7089.
   PubMed Web of Science ®Google Scholar
• Jessen NA, Munk AS, Lundgaard I, et al. The Glymphatic System: A Beginner’s Guide. Neurochem Res. 2015;40(12):2583–2599.
   PubMed Web of Science ®Google Scholar
• Johanns TM, Miller CA, Dorward IG, et al. Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. Cancer Discov. 2016;6(11):1230–1236.
   PubMed Web of Science ®Google Scholar
• Caccese M, Indraccolo S, Zagonel V, et al. PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review. Crit Rev Oncol Hematol. 2019;135:128–134.
   PubMed Web of Science ®Google Scholar
• Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget. 2017;8(53):91779–91794.
   PubMedGoogle Scholar
• Reardon DA, Omuro A, Brandes AA, et al. Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: checkMate 143. Neuro Oncol. 2017;19:iii21.
   Google Scholar
• Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–339.
   PubMed Web of Science ®Google Scholar
• Engelhardt B, Vajkoczy P, Weller RO. The movers and shapers in immune privilege of the CNS. Nat Immunol. 2017;18(2):123–131.
   PubMed Web of Science ®Google Scholar
• de Groot J, Penas-Prado M, Alfaro-Munoz KD, et al. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2019;22(4):539–549. doi:10.1093/neuonc/noz185
   Web of Science ®Google Scholar
• de Groot JF, Penas-Prado M, Mandel JJ, et al. Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma. J Clin Oncol. 2018;20(Suppl_ 6):vi2. doi:10.1093/neuonc/noy148.004
   Google Scholar
• Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477–486.
   PubMed Web of Science ®Google Scholar
• Kotecha R, Kim JM, Miller JA, et al. The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Neuro Oncol. 2019;21(8):1060–1068. doi:10.1093/neuonc/noz046
   Google Scholar
• Longo V, Brunetti O, Azzariti A, et al. Strategies to improve cancer immune checkpoint inhibitors efficacy, other than abscopal effect: a systematic review. Cancers (Basel). 2019;11:4.
   Web of Science ®Google Scholar
• Bago JR, Sheets KT, Hingtgen SD. Neural stem cell therapy for cancer. Methods. 2016;99:37–43.
   PubMed Web of Science ®Google Scholar
• Bago JR, Okolie O, Dumitru R, et al. Tumor-homing cytotoxic human induced neural stem cells for cancer therapy. Sci Transl Med. 2017;9:375.
   Web of Science ®Google Scholar